Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Oncoscience · 2015 · PMC4381710 · PMID 25859560

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The pattern of DHRS9 expression was similar to that of versican; however, the difference in expression did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.